Literature DB >> 9855033

A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts.

O Siddiqui1, M W Ali.   

Abstract

The last-observation-carried-forward imputation method is commonly used for imputting data missing due to dropouts in longitudinal clinical trials. The method assumes that outcome remains constant at the last observed value after dropout, which is unlikely in many clinical trials. Recently, random-effects regression models have become popular for analysis of longitudinal clinical trial data with dropouts. However, inference obtained from random-effects regression models is valid when the missing-at-random dropout process is present. The random-effects pattern-mixture model, on the other hand, provides an approach that is valid under more general missingness mechanisms. In this article we describe the use of random-effects pattern-mixture models under different patterns for dropouts. First, subjects are divided into groups depending on their missing-data patterns, and then model parameters are estimated for each pattern. Finally, overall estimates are obtained by averaging over the missing-data patterns and corresponding standard errors are obtained using the delta method. A typical longitudinal clinical trial data set is used to illustrate and compare the above methods of data analyses in the presence of missing data due to dropouts.

Mesh:

Year:  1998        PMID: 9855033     DOI: 10.1080/10543409808835259

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  24 in total

1.  Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study.

Authors:  Konasale M Prasad; Shaun M Eack; Dhruman Goradia; Krishna M Pancholi; Matcheri S Keshavan; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Am J Psychiatry       Date:  2011-06-01       Impact factor: 18.112

Review 2.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Handling missing quality of life data in HIV clinical trials: what is practical?

Authors:  Diane L Fairclough; Herbert Thijs; I-Chan Huang; Henrik W Finnern; Albert W Wu
Journal:  Qual Life Res       Date:  2007-12-11       Impact factor: 4.147

4.  Ulnar shortening osteotomy for ulnar-sided wrist pain.

Authors:  Masahiro Tatebe; Takanobu Nishizuka; Hitoshi Hirata; Ryogo Nakamura
Journal:  J Wrist Surg       Date:  2014-05

5.  Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Leon Aarons
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

6.  Early intervention options for acute low back pain patients: a randomized clinical trial with one-year follow-up outcomes.

Authors:  Travis Whitfill; Robbie Haggard; Samuel M Bierner; Glenn Pransky; Robert G Hassett; Robert J Gatchel
Journal:  J Occup Rehabil       Date:  2010-06

7.  On Inverse Probability Weighting for Nonmonotone Missing at Random Data.

Authors:  BaoLuo Sun; Eric J Tchetgen Tchetgen
Journal:  J Am Stat Assoc       Date:  2017-12-01       Impact factor: 5.033

8.  Applying an Instance-specific Model to Longitudinal Clinical Data for Prediction.

Authors:  Emily Watt; James W Sayre; Alex A T Bui
Journal:  Proc IEEE Int Conf Healthc Inform Imaging Syst Biol       Date:  2011-10-27

9.  The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.

Authors:  Craig H Mallinckrodt; Joel Raskin; Madelaine M Wohlreich; John G Watkin; Michael J Detke
Journal:  BMC Psychiatry       Date:  2004-09-08       Impact factor: 3.630

10.  The impact of analytic method on interpretation of outcomes in longitudinal clinical trials.

Authors:  A Prakash; R C Risser; C H Mallinckrodt
Journal:  Int J Clin Pract       Date:  2008-06-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.